Access
To read this story in full you will need to login or make a payment (see right).
Editorial
Nature Medicine 4, 1089 (1998)
doi:10.1038/2715
A duty to publish
Two years ago, the biomedical community learned that the drug company Boots Co. had funded University of California San Francisco (UCSF) researcher Betty Dong to conduct a trial on whether its expensive thyroid drug Synthroid was more effective than several cheaper alternatives.
To read this story in full you will need to login or make a payment (see right).
